A study that re-evaluated HER2 staining status in 281 breast cancer cases identified inter-observer variations in evaluating HER2 IHC staining, specifically for scores IHC 0 and IHC 1+ [24]. This evidence concerns the gene ERBB2 and breast carcinoma.